CI-1002, a Novel Anticholinesterase and Muscarinic Antagonist
The “cholinergic deficit hypothesis” provided the first theoretical framework for developing rational, palliative treatments for the cognitive loss associated with Alzheimer’s Disease (AD). The hypothesis arose from the synthesis of several lines of evidence showing the importance of central cholinergic function to normal cognition, and the relationship between AD dementia and the loss of cholinergic innervation to the neocortex and hippocampus (for a review see Davis et al., 1993). The “hypothesis” led to the testing of agents to restore central cholinergic function. A variety of replacement therapies were tried including inhibitors of acetylcholinesterase (AChE) to increase brain levels of acetylcholine. Initial studies using the anticholinesterase physostigmine provided suggestive evidence that such an approach might be beneficial (for a review see Kumar and Calache, 1991). However, early clinical results with tacrine (THA, Cognex®) sparked the effort to evaluate thoroughly the efficacy of cholinesterase inhibitors in the treatment of AD.
KeywordsMuscarinic Receptor AChE Activity Muscarinic Antagonist Aged Monkey Peripheral Anionic Site
Unable to display preview. Download preview PDF.
- Davis, K. L., Thal, L. J., Gamzu, E. R., Davis, C. S., Woolson, R. F., Gracon, S. I., Drachman, D. A., Schneider, L. S., Whitehouse, P. J., Hoover, T. I., Morris, J. C., Kawas, C. H., Knopman, D. S., Earl, N. L., Kumar, V. and Doody, R. S., 1992, A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer’s Disease, New Engl. J. Med. 327: 1253.PubMedCrossRefGoogle Scholar
- Kumar, V., and Calache, M., 1991, Treatment of Alzheimer’s disease with cholinergic drugs, Int. J. Clin. Pharm. Ther. Tox. 29: 23.Google Scholar
- Watson, M., Yamamura, H., and Roeske, W. R., 1986, [3H]pirenzepine and (-)-quinuclidinyl benzilate binding to rat cerebral cortical and cardiac muscarinic cholinergic sites. II. Characterization and regulation of antagonist binding to putative muscarinic subtypes, J. Pharmacol. Exp. Ther. 237: 4114.Google Scholar